All News
The RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read Article
NEJM Reviews Psoriatic Arthritis
A comprehensive review of psoriatic arthritis (PsA) was published this week in the NEJM, authored by leaders in the field, Drs. Ritchlin, Colbert and Gladman.
High points from their review inlcuded:
Read Article
The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read Article
European Biologic Manufacturers Issue Warnings About Biosimilar Switching
Reuters has reported that European drugmakers have taken the tact of warning EU physician contemplating the switch from existing (originator) biologic therapy to newer, cut-rate biosimilar. Biosimilar use is widespread outside the USA.
Read Article
Rheumatoid Progression Slowing Down
Patients with early rheumatoid arthritis (RA) with onset in the modern era had significantly lower baseline and annual rates of radiographic disease progression versus those with onset before 2001, researchers in England reported.
Read Article
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
Read Article
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. Many of these items were compiled from news sources, journal articles and regulatory documents and are cited and linked within each section.
Read Article
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Read Article
No Increase in Infections with Pre-Op Infliximab Before Hip or Knee Replacement
Up to 30% of patients with rheumatoid arthritis (RA) will eventually undergo joint reconstructive surgery, yet we have limited data to guide the perioperative management of DMARDs and biologics.
Read Article
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read Article
Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Read Article
Curbside Consults - January 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Read Article
The RheumNow Week in Review – 27 January 2017
Dr. Cush reviews highlights from the past week on RheumNow.com.
Read Article
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read Article
FDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read Article
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read Article
The RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read Article
The RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read Article
Pregnancy Outcomes in Psoriatic Arthritis
Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2